Welcome to the Bladder Cancer site of
Johns Hopkins Department of Pathology
Cancer of the bladder is the fourth most common malignancy among males and the tenth most common malignancy among females. Each year in the United States, over 50,000 people develop bladder cancer, of whom more than 12,000 ultimately will die of this disease.
Bladder cancer tends to occur most commonly in individuals over 60 years of age. Cigarette smoking and exposure to certain industrially used chemicals (derivatives of compounds called arylamines) are strongly associated with the development of bladder cancer. The vast majority (approximately 90%) of these cancers originate in the lining cells of the bladder, known as urothelium or transitional epithelium.
The Johns Hopkins Medical Institutions is a leader in the treatment and investigative study of bladder cancer. We have created this Web site to give patients and physicians access to the latest clinical and research developments related to this disease, as well as to the multidisciplinary team assembled here to fight bladder cancer.
TERT-Promoter Mutations Urine Assay for Early Detection and Monitoring of Bladder Cancer
Urothelial (transitional cell) bladder carcinoma is the 4th most common malignancy in American males with 72,570 new cases diagnosed in the US in 2013 leading to 15,210 deaths. Muscle invasive BC is responsible for most bladder cancer death.
© Copyright 2002-2016 Johns Hopkins University All Rights Reserved